Fluoxetine Fell Behind Three Antidepressants in Long-Term Study
A review of 115 clinical trials involving more than 30,000 people found that escitalopram, duloxetine and agomelatine performed better than fluoxetine at maintaining improvement in depression symptoms. Researchers cautioned that the findings cannot predict which medicine will work best for an individual patient.

Escitalopram, duloxetine and agomelatine outperformed the widely used antidepressant fluoxetine at helping people with depression stay well over time, a review of 115 clinical trials involving more than 30,000 people found.
The study, published in The Lancet Psychiatry, compared 20 antidepressants for both symptom relief and the prevention of returning symptoms. Researchers used fluoxetine as the main comparison drug.
The findings suggest some medicines may do more than ease symptoms: they may also help maintain improvement. They cannot show which antidepressant will work best for a specific person, researchers said.
Paul van Haaren, a researcher at Radboud University Medical Center who worked on the study, said the three medicines have different benefits and drawbacks.
“Escitalopram is already widely used,” van Haaren said. “Agomelatine works well, but one of its side effects is the risk of liver failure. Duloxetine is less well-known and is prescribed less frequently as a first-line treatment.”
Among the selective serotonin reuptake inhibitors (SSRIs) included in the study, escitalopram appeared to work best at helping patients stay well over time. SSRIs are a common group of antidepressants often recommended as a first treatment option.
Eric Ruhé, a professor of difficult-to-treat depression at Radboud University Medical Center, said the findings could eventually influence how doctors choose medicines. He cautioned that they do not mean everyone with depression should take escitalopram.
“As a prescriber, you consider the balance between a medication's benefits and side effects,” Ruhé said. “That balance differs from person to person.”
Dr. Carole Lieberman, a psychiatrist who was not involved in the study, said agomelatine is not approved in the United States. She also stressed that medication is not always the only treatment option.
“The best way to treat someone with depression is not always with antidepressants, and certainly not with antidepressants alone,” Lieberman said. She said talk therapy can play an important role, and some patients may benefit from combining it with medication.
The researchers combined results from earlier trials rather than enrolling and following a new group of patients. They said the findings cannot predict which antidepressant will work best for an individual.
People with questions about their antidepressants should speak with their doctor before making any changes, the researchers said.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds

- 2Micron Stock Falls 28% as $35.16 Billion Buyback Nears

- 3I’m A Celebrity 2026 Line-Up: Rooney Leads 11 Stars Into Jungle

- 4Taylor Swift and the Falcons Game Today: Chiefs in Atlanta

- 5Actor Says David Walliams Sexually Humiliated Him on Stage

Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists
LifestylePeople Who Don’t Like Celebrating Their Birthday Often Share These 7 Traits














